 Connection
Ping-Ching Hsu to Antineoplastic Agents
This is a "connection" page, showing publications Ping-Ching Hsu has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.060 |
|
|
|
-
Chen CB, Wang CW, Lu CW, Chen WT, Zhou BR, Chu CY, Hsu SF, Yang CT, Wen-Cheng Chang J, Yang CK, Wang CL, Fang YF, Hsu PC, Hua CC, Wu CE, Ko HW, Chen KC, Yang YC, Tseng HC, Cheng AY, Tseng LC, Shih FY, Hung SI, Huang CY, Chung WH. Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity. J Allergy Clin Immunol Pract. 2025 Jan; 13(1):143-154.e10.
Score: 0.033
-
Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021 Jul 27; 21(1):859.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|